Among its most severe forms are systemic lupus erythematosus (SLE) and lupus nephritis, conditions that significantly increase the risk of heart disease and kidney failure
Use of Liraglutide (Victoza, Saxenda) & Semaglutide (Ozempic, Wegovy, Rybelsus) Comes with Risk of Gastrointestinal Disorders Use of Liraglutide (Victoza, Saxenda) & Semaglutide (Ozempic, Wegovy, Rybelsus) Tied to Increased Risk for Pancreatitis and Bowel Obstruction A new study showed that use of the GLP1 agonist medications approved for diabetes and weight loss including liraglutide (Victoza, Saxenda) & semaglutide (Ozempic, Wegovy, Rybelsus) come with a 9X increased risk of pancreatitis, 4X increased risk of bowel obstruction and 3.5X increased risk of gastroparesis compared to controls
Were in this together.
Wegovy is approved for use by Hong Kong Department of Health, FDA and EMA
"Important update: required documentation for select ePA requests." Confirms GLP-1 medications require attached documentation for ePA
Fight Oxidative Stress: Oxidative stress caused by free radicals can worsen pigmentation